Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART

Annals of Nutrition and Metabolism

Volumn 50, Issue 3, 2006, Pages 247-252

  Uccelli, Maria Cristina ^a,b   Torti, Carlo ^a   Lapadula, Giuseppe ^a   Labate, Lorena ^a   Cologni, Giuliana ^a   Tirelli, Valeria ^a   Moretti, Francesca ^a   Costarelli, Silvia ^a   Quiros Roldan, Eugenia ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Inst of Infect and Trop Diseases   (Italy)

Author keywords

Folate; Highly active antiretroviral therapy; Homocysteinemia; Protease inhibitors; Vitamin B12

Indexed keywords

ANTIRETROVIRUS AGENT; FOLIC ACID; HOMOCYSTEINE; PROTEINASE INHIBITOR;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DRUG EXPOSURE; FEMALE; FOLIC ACID BLOOD LEVEL; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERHOMOCYSTEINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SURVIVAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; HIV INFECTIONS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; PROTEASE INHIBITORS; RISK FACTORS; TIME FACTORS;

EID: 33744801092     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091682     Document Type: Article

References (20)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Decline morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Lloeje U, Yuan Y, L'Italien G, Mauskopf J, Holmberg SD, Moorman AC, Wood KC, Moore RD: Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005;6:37-44.
3. Stanger O, Hermann W, Pietrzik K, Fowler B, Giesel J, Dierkes J, Weger M; DACH-LIGA Homocystein e.V. DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-1403.
4. Bernasconi E, Uhr M, Magenta L, Ranno A, Talenti A, the Swiss HIV cohort Study: Homocysteinemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 2001;15:1081-1082.
5. Holm PI, Ueland PM, Vollset SE, Midttund O, Blom HJ, Keijzer MB, den Heijer M: Betain and folate status as cooperative determinants of plasma homocysteine in humans. Arteroscler Thromb Vasc Biol 2005;25:379-385.
6. 12 abnormalities in HIV infected patients. Eur J Haematol 1991;47:60-64.
7. Look MP, Riezler R, Berthold HK, Stabler SP, Schliefer K, Allen RH, Sauerbruch T, Rockstroh JK: Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy. Metabolism 2001;50:1275-1281.
8. de Larranaga G, Alonso B, Puga L, Benetucci J: Plasma homocysteine in human immunodeficiency virus infected patient. Medicina (Buenos Aires) 2003;63:393-398.
9. Passalaris JD, Sepkowitz KA, Glesby MJ: Coronary artery and human immunodeficiency virus infection. Clin Infect Dis 2000;31:787-797.
10. Paton P, Tabib A, Loire R, et al: Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144:225-231.
11. Joshi VV, Pawel B, Connor E, et al: Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987;7:261-275.
12. Vilaseca MA, Sierra C, Colomé C, Artuch R, Valls C, Munoz-Almagro C, Vilches MA, Fortuny C: Hyperhomocysteinaemia and folate deficiency in human immunodeficiency virus-infected children. Eur J Clin Invest 2001;31:992-998.
13. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD, DAD Study Group: Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003;4:1-10.
14. 12 status. Am J Clin Nutr 2003;77:420-424.
15. Sheu WH, Chin HM, Lee WJ, Wan CJ, Su HY, Lang HF. Prospective evaluation of folic acid supplementation on plasma homocysteine concentrations during weight reduction: a randomized, double-blinded, placebo-controlled study in obese women. Life Sci 2005;76:2137-2145.
16. Klerk M, Durga J, Schouten EG, Kluft C, Kok FJ, Verhoef P. No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in older adults. Thromb Haemost 2005;94:96-100.
17. Stein JH, Bushara M, Bushara K, McBride PE, Jorenby DE, Fiore MC: Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels. Clin Cardiol 2002;25:23-26.
18. Durga J, van Tits LJH, Schouten EG, Kok FJ, Verhoef P: Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial. Arch Intern Med 2005;165:1388-1394.
19. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-375.
20. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.